Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 3/20 | 0.36 |
| ▸ | CKS1B | P61024 | 3/20 | 0.35 |
| ▸ | SKP1 | P63208 | 3/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LATS1 | O95835 | 2/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30471340 | 1.00 | GRM2 (0.37) | GRM2CFTRCKS1BSKP1SKP2 | |
| SCHEMBL30471261 | 0.93 | GRM2 (0.36) | GRM2CFTRCKS1BSKP1SKP2 | |
| SCHEMBL25686858 | 0.93 | GRM2 (0.36) | GRM2CFTRCKS1BSKP1SKP2 | |
| SCHEMBL25231387 | 0.89 | CKS1B (0.36) | CFTRCKS1BSKP1SKP2PDK2 | |
| SCHEMBL25686728 | 0.85 | CFTR (0.41) | GRM2CFTRCKS1BSKP1SKP2 | |
| SCHEMBL25686758 | 0.83 | CFTR (0.40) | GRM2CFTRCKS1BSKP1SKP2 | |
| SCHEMBL25234571 | 0.82 | CKS1B (0.35) | CFTRCKS1BSKP1SKP2PDK2 | |
| SCHEMBL23958787 | 0.80 | SLC34A1 (0.33) | CFTRPDK2 | |
| SCHEMBL30007885 | 0.80 | SLC34A1 (0.33) | CFTRPDK2 | |
| SCHEMBL25686999 | 0.80 | SLC34A1 (0.33) | CFTRPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021214136-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | GRM2 3975/4885CFTR 508/4885CKS1B 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.